Crucell to Release Q3 2009 Results on Tuesday November 3, 2009
(Thomson Reuters ONE) - Leiden, The Netherlands (October 27, 2009) - Dutch biopharmaceuticalcompany Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX)today announced that it will release its financial results for thethird quarter 2009 on Tuesday November 3, 2009 at 07:45 CentralEuropean Time (CET).At 14:00 Central European Time (CET), Crucell's management willconduct a conference call, which will also be webcast. To participatein the conference call, please call one of the following telephonenumbers 15 minutes prior to the event: +44 203 003 2666 for the UK; +1 646 843 4608 for the US; and +3120 794 8426 for the NetherlandsFollowing a presentation of the results, the lines will be opened fora question and answer session.The live audio webcast can be accessed via the homepage of Crucell'swebsite at www.crucell.com and will be archived and available forreplay following the event.About CrucellCrucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is aglobal biopharmaceutical company focused on research development,production and marketing of vaccines, proteins and antibodies thatprevent and/or treat infectious diseases. Its vaccines are sold inpublic and private markets worldwide. Crucell's core portfolioincludes a vaccine against hepatitis B, a fully-liquid vaccineagainst five important childhood diseases and a virosome-adjuvantedvaccine against influenza. Crucell also markets travel vaccines, suchas the only oral anti-typhoid vaccine, an oral cholera vaccine andthe only aluminum-free hepatitis A vaccine on the market. The Companyhas a broad development pipeline, with several product candidatesbased on its unique PER.C6® production technology. The Companylicenses its PER.C6® technology and other technologies to thebiopharmaceutical industry. Important partners and licensees includeDSM Biologics, Sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck &Co. Crucell is headquartered in Leiden, the Netherlands, withsubsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the USA.The Company employs over 1000 people. For more information, pleasevisit www.crucell.com.Forward-looking statementsThis press release contains forward-looking statements that involveinherent risks and uncertainties. We have identified certainimportant factors that may cause actual results to differ materiallyfrom those contained in such forward-looking statements. Forinformation relating to these factors please refer to our Form 20-F,as filed with the U.S. Securities and Exchange Commission on April22, 2009, in the section entitled 'Risk Factors'. The Companyprepares its financial statements under International FinancialReporting Standards (IFRS).Financial Calendar9 February 2010 Q4 Results 200911 May 2010 Q1 Results 20104 June 2010 Annual General Meeting of Shareholders17 August 2010 Q2 Results 20109 November 2010 Q3 Results 201015 February 2011 Q4 Results 2010For further information please contact:Crucell N.V.Oya YavuzVice PresidentCorporate Communications & Investor RelationsTel. +31-(0)71-519 7064ir(at)crucell.comwww.crucell.comhttp://hugin.info/132631/R/1350345/325785.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 27.10.2009 - 12:00 Uhr
Sprache: Deutsch
News-ID 7454
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 299 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Crucell to Release Q3 2009 Results on Tuesday November 3, 2009"
steht unter der journalistisch-redaktionellen Verantwortung von
Crucell N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
